Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. Issue 9 (11th December 2018)

• Record Type: Journal Article
• Authors: Cross, Amanda J; Wooldrage, Kate; Robbins, Emma C; Kralj-Hans, Ines; MacRae, Eilidh; Piggott, Carolyn; Stenson, Iain; Prendergast, Aaron; Patel, Bhavita; Pack, Kevin; Howe, Rosemary; Swart, Nicholas; Snowball, Julia; Duffy, Stephen W; Morris, Stephen; von Wagner, Christian; Halloran, Stephen P; Atkin, Wendy S
• Is Part Of: Gut. Volume 68:Issue 9(2019)
• Page Start: 1642
• Page End: 1652
• Publication Date: 2018-12-11
• Subjects: adenoma -- colorectal cancer -- surveillance -- stool markers -- colonoscopy; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-317297
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: The English Bowel Cancer Screening Programme (BCSP) recommends 3 yearly colonoscopy surveillance for patients at intermediate risk of colorectal cancer (CRC) postpolypectomy (those with three to four small adenomas or one ≥10 mm). We investigated whether faecal immunochemical tests (FITs) could reduce surveillance burden on patients and endoscopy services. Design: Intermediate-risk patients (60–72 years) recommended 3 yearly surveillance were recruited within the BCSP (January 2012–December 2013). FITs were offered at 1, 2 and 3 years postpolypectomy. Invitees consenting and returning a year 1 FIT were included. Participants testing positive (haemoglobin ≥40 µg/g) at years one or two were offered colonoscopy early; all others were offered colonoscopy at 3 years. Diagnostic accuracy for CRC and advanced adenomas (AAs) was estimated considering multiple tests and thresholds. We calculated incremental costs per additional AA and CRC detected by colonoscopy versus FIT surveillance. Results: 74% (5938/8009) of invitees were included in our study having participated at year 1. Of these, 97% returned FITs at years 2 and 3. Three-year cumulative positivity was 13% at the 40 µg/g haemoglobin threshold and 29% at 10 µg/g. 29 participants were diagnosed with CRC and 446 with AAs. Three-year programme sensitivities for CRC and AAs were, respectively, 59% and 33% at 40 µg/g, and 72% and 57% at 10 µg/g. Incremental costs per additional AA and CRC detected by colonoscopy versus FIT (40 µg/g) surveillance were £7354 and £180 778, respectively. Conclusions: Replacing 3 yearly colonoscopy surveillance in intermediate-risk patients with annual FIT could reduce colonoscopies by 71%, significantly cut costs but could miss 30%–40% of CRCs and 40%–70% of AAs. Trial registration number: ISRCTN18040196 ; Results.